Compare SMTI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTI | RCEL |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | 226 |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.2M | 126.8M |
| IPO Year | 2008 | N/A |
| Metric | SMTI | RCEL |
|---|---|---|
| Price | $24.55 | $5.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $34.00 | $7.88 |
| AVG Volume (30 Days) | 57.3K | ★ 346.8K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $15,586,976.00 | N/A |
| Revenue This Year | $17.31 | $17.17 |
| Revenue Next Year | $12.48 | $49.82 |
| P/E Ratio | $496.80 | ★ N/A |
| Revenue Growth | ★ 32.47 | N/A |
| 52 Week Low | $16.05 | $3.22 |
| 52 Week High | $35.70 | $7.12 |
| Indicator | SMTI | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 71.78 |
| Support Level | $20.47 | $5.03 |
| Resistance Level | $26.48 | $5.13 |
| Average True Range (ATR) | 1.38 | 0.29 |
| MACD | 0.21 | 0.11 |
| Stochastic Oscillator | 97.59 | 97.08 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.